Skin Products & Contact With Baby

Pregnancy

MotherToBaby reports that topical absorption can vary with product form, amount, body site and area, skin condition, and whether the skin is wet or dry; broken or irritated skin may allow more absorption. This concerns maternal absorption, not the amount transferred from a caregiver's skin to an infant after birth. For topical retinoids, ACOG and MotherToBaby describe precautionary pregnancy guidance, while ACOG notes that topical retinoids have low absorption. MotherToBaby’s specific tretinoin sheet says studies of proper topical use have not found a greater chance for birth defects, but it also notes case reports and says tretinoin has generally been not recommended during pregnancy. EMA's 2018 review says topical retinoid absorption is negligible and fetal harm is unlikely, but keeps a pregnancy contraindication as a precaution. The 2025 FDA-approved RETIN-A MICRO label says available topical tretinoin studies have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, and notes study limitations. In the 2026 Nordic cohort, 71 of 2,172 first-trimester exposed infants (3.3%) had a major malformation, compared with 111,404 of 3,671,023 unexposed infants (3.0%); the adjusted risk ratio was 1.1 (95% CI 0.87-1.38). The authors did not observe an increased risk but noted that limiting analysis to pregnancies resulting in birth could underestimate exposure and malformation risk. These findings concern topical retinoids, not all cosmetics or post-birth baby contact.

Breastfeeding

MotherToBaby’s topical-acne fact sheet limits its advice to OTC acne treatments and describes handwashing and washing a treated breast or chest area. For topical tretinoin, MotherToBaby says breastfeeding use has not been studied but very little is expected to enter the body or milk; LactMed also says there are no breastfeeding studies and considers topical use low risk because skin absorption is poor. LactMed advises against applying tretinoin directly to the nipple or areola and against direct infant contact with treated skin. The FDA-approved RETIN-A MICRO label reports no human-milk or infant data and advises using the smallest area for the shortest duration, without direct nipple or areola use. The Breastfeeding Network gives separate guidance for nipple products and sunscreen. The sources do not measure routine transfer for all cosmetics or establish a universal waiting time before holding an infant.

What was tested

The reviewed evidence does not include a study measuring routine transfer of a caregiver's lotion, perfume, sunscreen, or face cream to an infant. LactMed and MotherToBaby state that topical tretinoin has not been studied during breastfeeding; their ingredient-specific advice is based on low expected skin absorption, not measured milk transfer or routine infant contact. Dupuy et al. reviewed pediatric contact-allergy studies and list perfumes from parents, caregivers, or siblings as a possible fragrance exposure route, but did not measure residue transfer from a caregiver's skin. The 2026 Nordic cohort measured pregnancy outcomes after first-trimester topical-retinoid exposure, not milk levels or post-birth skin contact. The reviewed sources do not establish a universal waiting time for leave-on products before holding an infant.